Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539240 | 0.98 | KCNH2 (0.53) | KCNH2NOS2ESR1ESR2KMT2A | |
| SCHEMBL791579 | 0.90 | KCNH2 (0.46) | KCNH2NOS2ESR1ESR2KMT2A | |
| SCHEMBL5672228 | 0.83 | NOS2 (0.46) | KCNH2NOS2ESR1ESR2KMT2A | |
| SCHEMBL12483838 | 0.82 | KMT2A (0.42) | KCNH2NOS2ESR1ESR2KMT2A | |
| SCHEMBL13720052 | 0.82 | NOS2 (0.49) | KCNH2NOS2ESR1ESR2KMT2A | |
| SCHEMBL1187650 | 0.80 | KCNH2 (0.52) | KCNH2NOS2ESR1ESR2PTGS2 | |
| SCHEMBL8980571 | 0.80 | KCNH2 (0.52) | KCNH2NOS2ESR1ESR2PTGS2 | |
| SCHEMBL1189202 | 0.78 | KCNH2 (0.55) | KCNH2NOS2ESR1ESR2PTGS2 | |
| SCHEMBL1188035 | 0.78 | KCNH2 (0.55) | KCNH2NOS2ESR1ESR2PTGS2 | |
| SCHEMBL1187318 | 0.78 | KCNH2 (0.55) | KCNH2NOS2ESR1ESR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440531-B | 4H-imidazo [1,2-a ] imidazoles for electronic applications | UDC 爱尔兰有限责任公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-108299439-B | 4H-imidazo [1,2-a ] imidazoles for electronic applications | UDC 爱尔兰有限责任公司 | 2021-02-09 | — | — | CN | disclosed |
| US-9502664-B2 | 4H-imidazo[1,2-a]imidazoles for electronic applications | UDC IRELAND LIMITED (IE) | 2016-11-22 | — | — | US | disclosed |
| EP-2776443-B1 | 4H-IMIDAZO[1,2-A]IMIDAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2776443-A1 | 4H-IMIDAZO[1,2-A]IMIDAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-20140252280-A1 | 4H-IMIDAZO[1,2-A]IMIDAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2014-09-11 | — | — | US | disclosed |
| WO-2013068376-A1 | 4H-IMIDAZO[1,2-A]IMIDAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1948617-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | KCNH2 1831/4885NOS2 3670/4885ESR1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.